In Case You Missed It: Early vs Delayed Use of Antiretroviral Therapy to Reduce Transmission of HIV-1 in Serodiscordant Couples

A recent study published in the New England Journal of Medicine¬†reported that in 2014 there were more than 2 million new HIV-1 infections worldwide, most of which occurred via sexual transmission. Effective HIV-1 prevention strategies are required to reduce the risk of viral transmission from infected persons to their sexual partners. Other studies involving serodiscordant couples have suggested that antiretroviral therapy (ART) in those with HIV-1 infection reduces the risk of sexual transmission. The HIV Prevention Trials Network (HPTN) 052 trial, led by Myron S. Cohen, MD, was designed to determine the efficacy of antiretroviral therapy (ART) on preventing genetically-linked […]

In Case You Missed It: Daratumumab demonstrates significantly longer progression-free survival in multiple myeloma

Recently, results of a phase 3 trial performed by Antonio Palumbo, MD and other CASTOR investigators was published in the New England Journal of Medicine (N Engl J Med. 2016; 375:754-766) demonstrating the efficacy of daratumumab (16 mg/kg), an anti-CD38 monoclonal antibody, with bortezomib (1.3 mg/m2) plus dexamethasone (20 mg) in treatment of patients with relapses or relapsed and refractory multiple myeloma (n=498). Specifically, the¬†progression-free survival (60.7% vs 26.9%), overall response (82.9% vs 63.2%), very good partial response or better (59.2% vs 29.1%), and complete response (19.2% vs 9.0%) was superior in the daratumumab with bortezomib plus dexamethasone group than […]